STOCK TITAN

23andMe Appoints Three New Independent Directors to Board

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management

23andMe (Nasdaq: ME) has appointed three new independent directors to its Board: Andre Fernandez, Jim Frankola, and Mark Jensen, effective October 28, 2024. Each will serve on the Board's Audit and Compensation Committees, with Fernandez chairing Audit and Jensen serving as both Compensation Committee Chair and Lead Independent Director. The Board now consists of these three new directors alongside CEO and Co-Founder Anne Wojcicki. Jensen brings substantial financial experience from Deloitte, Frankola has extensive tech leadership background from Cloudera, and Fernandez previously served as WeWork's CFO.

23andMe (Nasdaq: ME) ha nominato tre nuovi direttori indipendenti nel suo Consiglio di Amministrazione: Andre Fernandez, Jim Frankola e Mark Jensen, con effetto dal 28 ottobre 2024. Ognuno di loro farà parte dei Comitati di Revisione e Retribuzione del Consiglio, con Fernandez che presiederà il Comitato di Revisione e Jensen che ricoprirà i ruoli di Presidente del Comitato di Retribuzione e Direttore Indipendente Principale. Il Consiglio ora è composto da questi tre nuovi direttori insieme all'Amministratore Delegato e Co-Fondatrice Anne Wojcicki. Jensen porta un'importante esperienza finanziaria da Deloitte, Frankola ha un'ampia esperienza nella leadership tecnologica da Cloudera e Fernandez ha precedentemente ricoperto il ruolo di CFO di WeWork.

23andMe (Nasdaq: ME) ha nombrado a tres nuevos directores independientes para su Junta: Andre Fernandez, Jim Frankola y Mark Jensen, con efecto a partir del 28 de octubre de 2024. Cada uno de ellos formará parte de los Comités de Auditoría y Compensación de la Junta, con Fernandez como presidente del Comité de Auditoría y Jensen como presidente del Comité de Compensación y Director Independiente Principal. La Junta ahora está compuesta por estos tres nuevos directores junto a la CEO y cofundadora Anne Wojcicki. Jensen aporta una experiencia financiera sustancial de Deloitte, Frankola tiene un amplio trasfondo de liderazgo tecnológico de Cloudera y Fernandez se desempeñó anteriormente como CFO de WeWork.

23andMe (Nasdaq: ME)는 이사회를 위해 새로운 독립 이사 세 명을 임명했습니다: Andre Fernandez, Jim Frankola, Mark Jensen입니다. 이들은 2024년 10월 28일부터 효력이 발생하며, 각각 감사위원회 및 보상위원회에서 활동할 예정입니다. Fernandez는 감사위원회 의장을 맡고, Jensen은 보상위원회 의장 및 수석 독립 이사로 활동합니다. 현재 이사회는 세 명의 새로운 이사와 CEO 겸 공동 창립자인 Anne Wojcicki로 구성되어 있습니다. Jensen은 Deloitte에서 상당한 재무 경험을 보유하고 있으며, Frankola는 Cloudera에서 폭넓은 기술 리더십 배경을 가지고 있고, Fernandez는 이전에 WeWork의 CFO로 근무했습니다.

23andMe (Nasdaq: ME) a nommé trois nouveaux administrateurs indépendants au sein de son Conseil d'Administration : Andre Fernandez, Jim Frankola et Mark Jensen, à compter du 28 octobre 2024. Chacun d'eux fera partie des Comités d'Audit et de Rémunération du Conseil, avec Fernandez en tant que président du Comité d'Audit et Jensen qui servira à la fois en tant que président du Comité de Rémunération et directeur indépendant principal. Le Conseil est désormais composé de ces trois nouveaux administrateurs aux côtés de la CEO et cofondatrice Anne Wojcicki. Jensen apporte une expérience financière substantielle de Deloitte, Frankola possède un large bagage en leadership technologique de Cloudera, et Fernandez a précédemment été CFO de WeWork.

23andMe (Nasdaq: ME) hat drei neue unabhängige Direktoren in seinen Vorstand berufen: Andre Fernandez, Jim Frankola und Mark Jensen, wirksam ab dem 28. Oktober 2024. Jeder wird in den Prüfungs- und Vergütungsausschüssen des Vorstands tätig sein, wobei Fernandez den Prüfungsausschuss leitet und Jensen als sowohl Vorsitzender des Vergütungsausschusses als auch als leitender unabhängiger Direktor fungiert. Der Vorstand besteht nun aus diesen drei neuen Direktoren sowie der CEO und Mitgründerin Anne Wojcicki. Jensen bringt umfangreiche Finanzerfahrung von Deloitte mit, Frankola hat umfassende Erfahrung in der Technologieführung von Cloudera und Fernandez war zuvor CFO von WeWork.

Positive
  • Addition of three experienced independent directors strengthens corporate governance
  • Appointment of dedicated Audit and Compensation Committee chairs enhances oversight
  • New directors bring significant financial and technology sector expertise
Negative
  • Significant board restructuring indicates potential need for strategic overhaul
  • Reduced board size from previous composition suggests streamlining of operations

SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company’s Board of Directors (the “Board”), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board’s Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In addition, Mr. Jensen has been appointed to serve as the Board’s Lead Independent Director.

The Board will now consist of the three new independent directors and Anne Wojcicki, the Company’s Chief Executive Officer, Co-Founder, and Chair of the Board.

“The new independent directors look forward to working closely with Anne Wojcicki and the Company’s management team to best position 23andMe for the future,” said Mr. Jensen. “23andMe has a great brand, and the Company remains firmly committed to its mission of helping people access, understand and benefit from the human genome. We are ready to dig in and act with urgency to get the Company on a path for long-term success.”

Ms. Wojcicki added, “I am excited to welcome these three experienced directors to the 23andMe Board, and looking forward to working with them.”

Mr. Jensen has substantial financial and corporate governance experience, having served as an advisor and board member in various companies in the technology sector. Prior to his retirement in 2012, Mr. Jensen was an executive at Deloitte & Touche LLP (“Deloitte”), where he served as U.S. Managing Partner-Audit and Enterprise Risk Services, Technology Industry and U.S. Managing Partner-Venture Capital Services Group. Before Deloitte, Mr. Jensen was the Chief Financial Officer at Redleaf Group, as well as an executive at the accounting firm Arthur Andersen LLP, where he was the Managing Partner of the Silicon Valley Office and led the company’s Global Technology Industry Practice. Mr. Jensen currently serves on the Board of Directors and Chair of the Audit Committee of Lattice Semiconductor Corporation (Nasdaq: LSCC).

Mr. Fernandez, a seasoned executive with extensive cross-industry leadership experience, most recently served as the Chief Financial Officer of WeWork, Inc. Prior to joining WeWork, Inc., he was the Executive Vice President and Chief Financial Officer of NCR Corporation, a global enterprise technology provider of digital commerce solutions for financial institutions, retail stores, and restaurants, and the President and Chief Executive Officer of CBS Radio Inc. Mr. Fernandez currently serves on the Board of Directors and the Audit Committee of Cardlytics, Inc. (Nasdaq: CDLX).

A practiced leader and advisor in the technology space, Mr. Frankola most recently served as the Chief Financial Officer and a strategic advisor to Cloudera, Inc., an enterprise data cloud company. Prior to Cloudera, Inc., Mr. Frankola was the Chief Financial Officer of Yodlee, Inc., a data aggregation and analytics platform, and Ariba, Inc., a leading procurement and supply chain management technology provider. He currently serves on the Board of Directors and Chair of the Audit Committee of Ansys, Inc. (Nasdaq: ANSS) and on the Board of Directors and the Audit Committee of Skillsoft Corp. (NYSE: SKIL). Additionally, Mr. Frankola is an advisor to the artificial intelligence companies Vectara and Narada.

About 23andMe
23andMe is a genetics-led consumer healthcare and biopharmaceutical company empowering a healthier future. For more information, please visit www.23andMe.com.

Contact
press@23andme.com
investors@23andme.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “predicts,” “continue,” “will,” “schedule,” and “would” or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.


FAQ

Who are the new board directors appointed to 23andMe (ME)?

23andMe appointed Andre Fernandez, Jim Frankola, and Mark Jensen as independent directors effective October 28, 2024.

What positions will the new 23andMe (ME) directors hold?

Andre Fernandez will chair the Audit Committee, Mark Jensen will chair the Compensation Committee and serve as Lead Independent Director, and all three will serve on both committees.

How many members are now on 23andMe's (ME) board of directors?

The board now consists of four members: the three new independent directors and CEO Anne Wojcicki, who serves as Board Chair.

23andMe Holding Co.

NASDAQ:ME

ME Rankings

ME Latest News

ME Stock Data

82.79M
18.44M
3.65%
33.33%
3.98%
Diagnostics & Research
Pharmaceutical Preparations
Link
United States of America
SUNNYVALE